Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

PEG-3350 and Electrolytes

&times

Overview

What is PEG-3350 and Electrolytes?

A white powder in a 4 liter jug for reconstitution, containing 236 g polyethylene glycol 3350, 22.74 g sodium sulfate (anhydrous), 6.74 g sodium bicarbonate, 5.86 g sodium chloride and 2.97 g potassium chloride. When dissolved in water to a volume of 4 liters, PEG-3350 and Electrolytes for Oral Solution is an isosmotic solution having a mildly salty taste. PEG-3350 and Electrolytes for Oral Solution is administered orally or via nasogastric tube as a gastrointestinal lavage.



What does PEG-3350 and Electrolytes look like?



What are the available doses of PEG-3350 and Electrolytes?

Sorry No records found.

What should I talk to my health care provider before I take PEG-3350 and Electrolytes?

Sorry No records found

How should I use PEG-3350 and Electrolytes?

PEG-3350 and Electrolytes for Oral Solution is indicated for bowel cleansing prior to colonoscopy and barium enema X-ray examination.

The recommended dose for adults is 4 liters of PEG-3350 and Electrolytes for Oral Solution solution prior to gastrointestinal examination, as ingestion of this dose produces a satisfactory preparation in over 95% of patients. Ideally, the patient should fast for approximately three or four hours prior to PEG-3350 and Electrolytes for Oral Solution administration, but in no case should solid food be given for at least two hours before the solution is given.

PEG-3350 and Electrolytes for Oral Solution is usually administered orally, but may be given via nasogastric tube to patients who are unwilling or unable to drink the solution. is at a rate of 240 mL (8 oz.) every 10 minutes, until 4 liters are consumed or the rectal effluent is clear. Rapid drinking of each portion is preferred to drinking small amounts continuously. is at the rate of 20-30 mL per minute (1.2-1.8 liters per hour). The first bowel movement should occur approximately one hour after the start of PEG-3350 and Electrolytes for Oral Solution administration.

Various regimens have been used. One method is to schedule patients for examination in midmorning or later, allowing the patients three hours for drinking and an additional one hour period for complete bowel evacuation. Another method is to administer PEG-3350 and Electrolytes for Oral Solution on the evening before the examination, particularly if the patient is to have a barium enema.


What interacts with PEG-3350 and Electrolytes?

Sorry No Records found


What are the warnings of PEG-3350 and Electrolytes?

Sorry No Records found


What are the precautions of PEG-3350 and Electrolytes?

Sorry No Records found


What are the side effects of PEG-3350 and Electrolytes?

Sorry No records found


What should I look out for while using PEG-3350 and Electrolytes?

PEG-3350 and Electrolytes for Oral Solution is contraindicated in patients known to be hypersensitive to any of the components. PEG-3350 and Electrolytes for Oral Solution is contraindicated in patients with gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon or ileus.

No additional ingredients, e.g. flavorings, should be added to the solution. PEG-3350 and Electrolytes for Oral Solution should be used with caution in patients with severe ulcerative colitis.


What might happen if I take too much PEG-3350 and Electrolytes?

Sorry No Records found


How should I store and handle PEG-3350 and Electrolytes?

Store between 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).Do not refrigerate. Keep the bottle in the outer carton when not in use.The product should be used within three months after it has been opened.Store between 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).Do not refrigerate. Keep the bottle in the outer carton when not in use.The product should be used within three months after it has been opened.Store between 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).Do not refrigerate. Keep the bottle in the outer carton when not in use.The product should be used within three months after it has been opened.In powdered form, for oral administration as a solution following reconstitution. PEG-3350 and Electrolytes for Oral Solution is available in a disposable jug in powdered form containing: In powdered form, for oral administration as a solution following reconstitution. PEG-3350 and Electrolytes for Oral Solution is available in a disposable jug in powdered form containing:


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

PEG-3350 and Electrolytes for Oral Solution induces a diarrhea which rapidly cleanses the bowel, usually within four hours. The osmotic activity of polyethylene glycol 3350 and the electrolyte concentration result in virtually no net absorption or excretion of ions or water. Accordingly, large volumes may be administered without significant changes in fluid or electrolyte balance.

Non-Clinical Toxicology
PEG-3350 and Electrolytes for Oral Solution is contraindicated in patients known to be hypersensitive to any of the components. PEG-3350 and Electrolytes for Oral Solution is contraindicated in patients with gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon or ileus.

No additional ingredients, e.g. flavorings, should be added to the solution. PEG-3350 and Electrolytes for Oral Solution should be used with caution in patients with severe ulcerative colitis.

Drug Interactions:

General:

Nausea, abdominal fullness and bloating are the most common adverse reactions (occurring in up to 50% of patients) to administration of PEG-3350 and Electrolytes for Oral Solution. Abdominal cramps, vomiting and anal irritation occur less frequently. These adverse reactions are transient and subside rapidly. Isolated cases of urticaria, rhinorrhea, dermatitis and (rarely) anaphylactic reaction have been reported which may represent allergic reactions.

Published literature contains isolated reports of serious adverse reactions following the administration of PEG-ELS products in patients over 60 years of age. These adverse events include upper GI bleeding from Mallory-Weiss Tear, esophageal perforation, asystole, sudden dyspnea with pulmonary edema, and “butterfly-like” infiltrates on chest X-ray after vomiting and aspirating PEG.

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).